|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
He C, Mao D, Hua G, Lv X, Chen X,
Angeletti PC, Dong J, Remmenga SW, Rodabaugh KJ, Zhou J, et al: The
Hippo/YAP pathway interacts with EGFR signaling and HPV
oncoproteins to regulate cervical cancer progression. EMBO Mol Med.
7:1426–1449. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang W, Nandakumar N, Shi Y, Manzano M,
Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et
al: Downstream of mutant KRAS, the transcription regulator YAP is
essential for neoplastic progression to pancreatic ductal
adenocarcinoma. Sci Signal. 7:ra422014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ,
Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al:
Overexpression of YAP 1 contributes to progressive features and
poor prognosis of human urothelial carcinoma of the bladder. BMC
Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He C, Lv X, Hua G, Lele SM, Remmenga S,
Dong J, Davis JS and Wang C: YAP forms autocrine loops with the
ERBB pathway to regulate ovarian cancer initiation and progression.
Oncogene. 34:6040–6054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Shi S, Guo Z, Zhang X, Han S, Yang
A, Wen W and Zhu Q: Overexpression of YAP and TAZ Is an independent
predictor of prognosis in colorectal cancer and related to the
proliferation and metastasis of colon cancer cells. PLoS One.
8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Yang S, Chen X, Stauffer S, Yu F,
Lele SM, Fu K, Datta K, Palermo N, Chen Y and Dong J: The hippo
pathway effector YAP regulates motility, invasion, and
castration-resistant growth of prostate cancer cells. Mol Cell
Biol. 35:1350–1362. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang SP, Zhang L, Purohit V, Shukla SK,
Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, et al: Active YAP
promotes pancreatic cancer cell motility, invasion and
tumorigenesis in a mitotic phosphorylation-dependent manner through
LPAR3. Oncotarget. 6:36019–36031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muramatsu T, Imoto I, Matsui T, Kozaki K,
Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP
is a candidate oncogene for esophageal squamous cell carcinoma.
Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin D, Wu Y, Shao C, Gao Y, Wang D and Guo
J: Norcantharidin reverses cisplatin resistance and inhibits the
epithelial mesenchymal transition of human nonsmall lung cancer
cells by regulating the YAP pathway. Oncol Rep. 40:609–620.
2018.PubMed/NCBI
|
|
16
|
Kulkarni M, Tan TZ, Syed Sulaiman NB,
Lamar JM, Bansal P, Cui J, Qiao Y and Ito Y: RUNX1 and RUNX3
protect against YAP-mediated EMT, stem-ness and shorter survival
outcomes in breast cancer. Oncotarget. 9:14175–14192. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thongon N, Castiglioni I, Zucal C, Latorre
E, D'Agostino V, Bauer I, Pancher M, Ballestrero A, Feldmann G,
Nencioni A and Provenzani A: The GSK3β inhibitor BIS I reverts
YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs
expression level. Oncotarget. 7:26551–26566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu S, Jing L, Yin XR, Wang MC, Chen YM,
Guo Y, Nan KJ and Han LL: MiR-195 suppresses the metastasis and
epithelial-mesenchymal transition of hepatocellular carcinoma by
inhibiting YAP. Oncotarget. 8:99757–99771. 2017.PubMed/NCBI
|
|
19
|
Cui M and Li Z: Downregulation of YAP
inhibits proliferation and induces apoptosis in Eca-109 cells. Exp
Ther Med. 15:1048–1052. 2018.PubMed/NCBI
|
|
20
|
Rice TW, Ishwaran H, Ferguson MK,
Blackstone EH and Goldstraw P: Cancer of the Esophagus and
Esophagogastric Junction: An Eighth Edition Staging Primer. J
Thorac Oncol. 12:36–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song S, Ajani JA, Honjo S, Maru DM, Chen
Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, et al:
Hippo coactivator YAP1 upregulates SOX9 and endows esophageal
cancer cells with stem-like properties. Cancer Res. 74:4170–4182.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin WC, Ding YF, Hsu HL, Chang JH, Yuan
KS, Wu ATH, Chow JM, Chang CL, Chen SU and Wu SY: Value and
application of trimodality therapy or definitive concurrent
chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
Cancer. 123:3904–3915. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Cheng B, Wang C, Chen P and Cheng
Y: The prognostic significance of metabolic syndrome and weight
loss in esophageal squamous cell carcinoma. Sci Rep. 8:101012018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Z, Zeng W, Wang S, Zhao X, Guo Y, Yu
P, Yin X, Liu C and Huang T: A potential role for the Hippo pathway
protein, YAP, in controlling proliferation, cell cycle progression,
and autophagy in BCPAP and KI thyroid papillary carcinoma cells. Am
J Transl Res. 9:3212–3223. 2017.PubMed/NCBI
|
|
25
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim
J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP
oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin K, Dang S, Cui L, Fan X, Xie R, Qu J,
Shang M and Chen J: Corrigendum to ‘Netrin-1 promotes metastasis of
gastric cancer by regulating YAP activity’ [Biochem. Biophys. Res.
Commun.496 (1) (2018 Jan 29) 76–82]. Biochem Biophys Res Commun.
498:2622018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Attisano L and Wrana JL: Signal
integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep.
5:172013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cottini F, Hideshima T, Xu C, Sattler M,
Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri
A, et al: Rescue of Hippo coactivator YAP1 triggers DNA
damage-induced apoptosis in hematological cancers. Nat Med.
20:599–606. 2014. View
Article : Google Scholar : PubMed/NCBI
|
